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Effect of Interval between Neutron
Radiation and Diethyistilbestrol on
Mammary Carcinogenesis in Female ACI
Rats
by Claire J. Shellabarger,* J. Patrick Stone* and
Seymour Holtzman*
Both radiation and diethylstilbestrol (DES) are carcinogens for the mammary gland of ACI female
rats. When DES is given at about the same time as radiation, DES and radiation interact in a syner-
gistic fashion particularly in regard to the number of mammary adenocarcinomas per rat. We have
studied the effect of increasing the time interval between radiation and DES on the capacity of DES
to enhance (promote?) radiation-induced mammary carcinogenesis. DES, in the form of a com-
pressed pellet containing a mixture of cholesterol and DES, formulated to average 1.25 mg of
DES/100 gr body weight, was given to groups of approximately 28 rats at 2 days before, or 50, 100
or 200 days after 0.064 Gy of 0.43 MeV neutron radiation. At each time that DES was given to irra-
diated rats, DES was also given to nonirradiated rats. All rats were studied for 375 days after the
date of the DES administration. When the total number of mammary adenocarcinomas was calcu-
lated as a percentage of 24 sites per rat at-risk, DES and radiation always produced a response that
was larger than the sum of the responses of DES alone plus radiation alone. This result suggests
that these two agents can interact in a synergistic fashion. The interaction between radiation and
DES did not decline as the time interval between radiation and DES was lengthened. This result
suggests that radiation-induced (initiated?) mammary carcinogenesis is not subject to repair since
DES enhancement (promotion?) continues to be effective over long time intervals.
Introduction
In female ACI rats it has been shown by Segaloff
and Maxfield (1) and Shellabarger et al. (2) that a di-
ethylstilbestrol (DES) pellet, implanted subcu-
taneously 2 days before total body x-ray or neutron
irradiation, enhances radiation-induced mammary
carcinogenesis. The experiment to be described
addresses the question: if time were allowed to
elapse between the application of radiation and the
insertation of the DES pellet, would mammary car-
cinogenesis be reduced? Such a result would imply
that during the interval between radiation and DES
treatment, radiation-induced carcinogenic events
would have been repaired and would no longer be
available for DES enhancement.
*Medical Department, Brookhaven National Laboratory,
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Materials and Methods
Female ACI rats were produced by our Brook-
haven breeding colony. DES-cholesterol pellets
were made as previously described (2). A mixture of
DES and cholesterol, or cholesterol only was formed
by compression to obtain a 20 mg pellet. The pellet
was implanted subcutaneously in the intrascapular
region under ether anesthesia. The DES-cholesterol
pellets were formulated to contain 1.25 mg of
DES/100 g body weight. Neutron irradiation with
0.43 MeV neutrons at 0.064 Gy (6.4 rad) was done as
previously described (3). The 12 experimental
groups are shown in Table 1.
Group 0 comprised untreated controls (Table 1).
Group 1 received a cholesterol pellet on day 75 of
age and radiation on day 77. Group 2 received the
DES pellet on day 75 of age. Group 3 received the
DES pellet at 75 days of age and neutron irradiation
on day 77, and the interval is referred to as -2 days.SHELLABARGER, STONEAND HOLTZMAN
Group 4 received neutron irradiation on day 77 of
age and the cholesterol pellet on day 127. Group 5
received the DES pellet on day 127 of age. Group 6
received radiation on day 77 of age and DES on day
127, and the interval is referred to as + 50 days.
Similarly, Group 7 received radiation on day 77, and
cholesterol on day 177. Group 8 received DES on
day 177 of age, group 9 received radiation at 77
days and DES at 177 days of age, and the interval is
referred to as + 100 days. Group 10 received radia-
tion at 77 days and cholesterol at 277 days of age.
Group 11 received DES at 277 days of age. Group
12 received radiation at 77 days and DES at 277
days of age, and the interval is referred to as + 200
days.
All tumor and survival data were reckoned as
days after the date of the DES pellet implantation.
All rats were maintained on commercial rat chow
and water ad libitum, with 12 hr (8 A.M. to 8 P.M.)
of fluorescent light per day, at 22.5 ± 10C and 55%
+ 10% humidity (RH). Each rat was identified by a
numbered ear tag. The rats were palpated once per
week, and the anatomical location of each mammary
tumor was recorded using the nipples as reference
points. Whenever a mammary tumor grew to about
1 cm in the largest dimension, it was removed un-
der ether anesthesia. If a second tumor was found
at the site of a previous tumor it was not recorded
as a new tumor unless the site had been tumor-free
for 90 days. Mammary tumors were fixed, sec-
tioned, stained with hematoxylin and eosin, and giv-
en a pathological classification of either mammary
adenocarcinoma (AC) or fibroadenoma (FA) accord-
ing to the criteria of Young and Hallowes (4). If
there were six or more mammary tumors within a
single quadrant of breast tissue at one time, the en-
tire quadrant of breast tissue was removed, fixed,
defatted, stained with hematoxylin, and cleared in
methyl salicylate and the individual mammary ade-
nocarcinomas counted using 10 x magnification.
The maximum total number of mammary adenocar-
cinomas per quadrant was taken to be no more than
six, although this was probably an underestimate.
Quadrants were removed only at the maximum rate
of 1 per week. At the time for the fourth quadrant
removal, the rat was killed. Rats were also killed
when they became moribund or when 375 days had
elapsed after the date of DES pellet implantation.
At autopsy, each rat was examined for gross patho-
logical changes and all DES pellets were recovered
to confirm their presence. Abnormal pituitary
glands were recorded as tumors if they were hem-
orrhagic and fragile, or if they exceeded 30 mg in
weight.
The incidence of rats with one or more mammary
adenocarcinomas was calculated both as percent of
the starting number of rats and as the percent of
rats at-risk by the method of Kaplan and Meier (5).
The data on rats with one or more mammary adeno-
carcinomas was evaluated by the chi-square test,
the Cox test, the Kruskal-Wallis test, and Cox's
exact trend analysis using a program provided by
Thomas et al. (6).
In order to analyze the incidence of the total num-
ber of mammary adenocarcinomas per rat per ex-
perimental group, we have chosen to use the follow-
ing procedure. It is assumed that each rat has the
capacity to develop 24 mammary adenocarcinomas.
Twenty-four (six tumors per quadrant times four
quadrants) was chosen as the maximum number be-
cause we often find rats with 24 or more mammary
adenocarcinomas so that the potential for the devel-
opment of at least 24 is established. Also, we have
chosen 24 as the maximum number because this is
toward the upper limit of individual mammary car-
cinomas that we believe we can count accurately be-
cause of overgrowth and possible fusion of adeno-
carcinomas. Thus, in an experimental group of 30
rats, there are 30 rats times 24 potential adenocarci-
noma sites per rat, or a total of 720 potential adeno-
carcinoma sites in the group. If one rat develops a
single adenocarcinoma, this is an incidence of
0.140%. If either this rat develops a second adenocar-
cinoma, or if another rat develops a single adenocar-
cinoma, the result would be a 0.280% response for
the group. The at-risk calculation is made as follows.
Each time an adenocarcinoma occurs, there is one
less potential tumor site at risk. When a rat dies, all
of its tumor-free sites are subtracted from the
group total potential sites since they are no longer
at risk. The data on the total number of tumors per
group were evaluated, again by using the program
of Thomas et al. (6).
Results
DES treatment tended to reduce the rate of
survival and consequently the number of days in
the study (Table 1). When radiation was combined
with DES, the rate of survival and the number of
days in the study were further reduced. In general,
the older the rats were at the time of DES treat-
ment, the greater the reduction in survival rate and
days of study. These results suggest that survival
rate should be taken into account when analyzing
tumor incidence. There were so few fibroadenomas
that they were not analyzed.
Almost every rat treated with DES developed at
least one mammary adenocarcinoma (Table 1). In
only one instance (+ 50 days DES groups) did
radiation combined with DES induce a higher final
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Table 1. Treatment, number, survivors, and mammary adenocarcinoma data.a
All
Rats with mammary adenocarcinomas,
Treatment Days adenocarcinomasb (maximum of 24 per rat per group)b
and Days Interval, Survivors, studied, K-M MTA, K-M MTA,
Group of Age days N % +± SD N % % / + SD N % % x± SD
0 None 31 97 575 ± 7 1 3 3 575 - 1 0.13 0.13 575 -
1 Chol, 75 24 100 375 - 1 4 4 375 - 1 0.04 0.17 375 -
Rad, 77
2 DES, 75 -2 22 64 347 ± 44 19 86 86 254 ± 75 169 32.0 36.5 303 ± 66
3 DES, 75 24 42 321 ± 60 23 96 96 222 ± 61 313 54.3d 62.7 277 67d
Rad,77 -2
4 Rad,77 24 100 375 - 1 4 4 325 - 1 0.04 0.17 325 -
Chol, 127
5 DES, 127 + 50 30 83 365 ± 24 19 63 63 299 ± 52 111 15.4 16.6 332 40
6 Rad,77 31 62 324 ± 69 29 94b 96 241 ± gob 335 45.0 d 52.3 266 78d
DES, 127 + 50
7 Rad,77 24 92 373 ± 7 5 21 21 334 ± 37 5 0.9 0.9 334± 37
Chol, 177
8 DES, 177 + 100 28 86 365 ± 29 27 96 100 241 ± 90 123 18.3 20.8 330 ± 67
9 Rad, 77 32 50 320 ± 95 30 94 94 203 ± 91 395 51.4 d 55.1 253 ± 77d,f
DES, 177 + 100
10 Rad,77 24 71 357 ± 37 8 33 36 257 ± 43 20 3.5 4.1 311 + 13
Chol, 277
11 DES, 277 + 200 30 67 317 ± 62 27 90 100 232 ± 78 203 28.2 43.1 293 ± 68
12 Rad, 77 27 11 267 ± 78 27 100 100 155 ± 53c 330 50.9 d 77.8 240 ± 79d,e
DES, 277 + 200
aCholesterol (CHOL) pellet, 20 mg compressed diethylstilbestrol-cholesterol pellet formulated to contain 1.25 mg of
diethylstilbestrol/100 g body weight (DES); 0.064 Gy of neutron radiation (RAD); at various days of age. K-M% denotes Kaplan-
Meier % (K-M%); MTA is mean time of appearance.
bGroup 5 vs. Group 6, x2 = 0.0109, Cox = 0.0007, K/W = 0.0003.
cGroup 12 vs. Group 11, Cox = 0.0001, K/W = 0.0001 and Group 12 vs. Group 3, Cox = 0.0004, K/W = 0.001 and Group 12 vs.
Group 6, Cox = 0.0001, K/W = 0.0001 and Group 12 vs. Group 9, Cox = 0.0041, K/W = 0.0079.
dGroup 2 vs. Group 3 and Group 5 vs. Group 6 and Group 8 vs. Group 9,X2 = 0.0001, Cox = 0.001, K/W = 0.0001.
eGroup 12 vs. Group 9, Cox = 0.0001, K/W = 0.0001, and Group 12 vs. Group 6, = 0.0321, Cox = 0.0001, K/W = 0.0001 and
Group 12 vs. Group 3, Cox = 0.0001, K/W = 0.0001.
fGroup 9 vs. Group 6, X2 = 0.0147, Cox = 0.0222, K/W = 0.0030.
cumulative incidence than DES given alone, DES at
127 days = 63% and radiation at 77 days combined
with DES at 127 days = 94%. However, Cox's
exact trend analyses of these data indicated that
there was a significantly earlier appearance of rats
developing a first mammary adenocarcinoma when
they were given both radiation and DES as com-
pared to DES alone (Fig. 1). Increasing the interval
between radiation and DES treatments tended to
produce an earlier response (Fig. 1 and Table 1).
For all DES treatment intervals, the combined
treatment (DES plus radiation) produced more total
mammary adenocarcinomas (calculated as the per-
cent at risk of a maximum of 24 mammary adeno-
carcinomas per rat multiplied by the number of rats
in the group) than either radiation alone, or DES
alone, or the sum of the tumors from radiation alone
or DES alone (Table 1). This suggests that radiation
and DES interacted synergistically. Also, the adeno-
carcinomas tended to occur earlier in the combined
radiation and DES groups than in either the DES
alone or radiation alone groups. There appeared to
be no tendency toward a decline in mammary aden-
ocarcinoma incidence as the time between radiation
and DES was increased as shown by either of two
comparisons. First, when the ratio of the incidence
of mammary adenocarcinomas in the combined radi-
ation and DES groups was compared to the "ex-
pected" incidence of radiation alone plus DES alone,
the ratio at -2 days of 1.71 changed to 3.12 at + 50
days, to 2.54 and 1.65 at + 100 and + 200 days, re-
spectively (Fig. 2). Secondly, when the ratio of the
incidence in the combined radiation and -2 days
group was compared to the incidence of the com-
bined radiation and + 50 days DES, radiation + 100
days and radiation + 200 days, the ratio was 0.83,
0.88 and 1.24 respectively (Fig. 2). Again no ten-
dency for a decrease in response was noted as the
interval between radiation and DES was increased.
Pituitary tumors were found in 47% of the
untreated rats, in 60% of the rats that were irradi-
ated, in 95% of the DES-treated rats, and in 95% of
the rats treated with the combination of radiation
and DES.
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FIGURE 1. Percentage of rats (at risk) with a mammary adenocarcinoma (MAC) for each treatment group plotted as a function of
time in days after DES-cholesterol pellet implantation. -2, + 50, + 100, + 200 are intervals in days between pellet im-
plantation and irradiation; N = 0.064 Gy of 0.43 MeV neutron radiation; DES, 1.25 mg DES/100 g body weight in a 20 mg
compressed DES-cholesterol pellet; Chol, pellet contained cholesterol only. p Values are obtained from Cox's exact trend
analyses of the data.
Discussion
With some reservations, we have chosen to dis-
cuss these results in terms of radiation as an initia-
tor and DES as a promoter. Some of the reasons for
this approach are given below.
DES is a carcinogen, and in this experiment it is
again shown to be a carcinogen for mammary ade-
nocarcinoma induction in the female ACI rat. How-
ever, as discussed by Roe (7), there is little evidence
that DES is a initiator, in any biological system. In
the present biological system, it is probably true
that DES, acting as an estrogen as shown else-
where (8), increases prolactin levels (9), and it is
these high prolactin levels, or the high ratio of pro-
lactin to estrogen, that in turn interact with radia-
tion to enhance radiation carcinogenesis. In the
Sprague-Dawley rat mammary adenocarcinoma sys-
tem it has been shown that if prolactin is given be-
fore DMBA, then prolactin inhibits DMBA-induced
mammary carcinogenesis as discussed by Weloch
and Nagasawa (10). These circumstances suggest
that DES fulfills one of the requirements of a pro-
motor-it is not an effective enhancer of carcinogen-
esis when given before the presumed initiator but is
effective when given after the presumed initiator.
In the present experiment DES did increase the in-
cidence of pituitary tumors which has been shown
before to be correlated with high prolactin levels (9).
Since it takes some time to increase prolactin levels
(9), even though DES, in one instance, was given be-
fore radiation, the real enhancer-prolactin-was
present in increased amounts only some time after
radiation. Prolactin levels from the rats in the pres-
ent experiment are being measured in an attempt
to confirm this inference.
Radiation in high dosages also is a carcinogen for
mammary carcinogenesis. However, in the present
experiment, if radiation were a weak complete car-
cinogen, it could only be at best a weak promoter, in
the dose used. We prefer to think that in the
present experiment radiation acted as an initiator.
The objective of the present experiment was to
see, if, after a delay in DES administration, would
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FIGURE 2. Histogram of all mammary adenocarcinomas as
percent of 24 sites at risk per rat per group. OBS denotes
observed percent in group that received both radiation
and DES. EXP shows expected percent if the interaction
of radiation and DES were additive, sum of observed in
irradiated group plus observed in DES group. Open bars
represent percent of 24 tumors per rat. Hatched bars plus
open bars, represent percent of 24 tumors per rat at risk
(Kaplan-Meier).
DES retain its capacity to enhance radiation-
initiated mammary adenocarcinoma formation. We
believe the answer to this question is yes.
When mammary carcinogenesis was studied
(measured) in terms of the incidence of rats (at risk)
with one or more mammary adenocarcinomas, there
was a significant trend for the rats that received
both DES and radiation to develop tumors sooner
than the rats that received only DES. However,
when all mammary adenocarcinomas were consid-
ered, there were two ways to analyze the effect of a
delay between the administration of radiation and
DES. Firstly, it is clear that when both radiation
and DES were given the response was larger than
the sum of radiation alone plus DES alone. When
this synergistic interaction between radiation and
DES was studied at four intervals between radia-
tion and DES, the relative amount of synergism (ra-
diation and DES/radiation plus DES) was not very
different. At -2 days, it was 1.71; at + 50 days, 3.12;
at + 100 days, 2.54; at + 200 days, 1.65. Clearly,
there was no regular decline in synergism as the in-
terval between radiation and DES was increased.
Thus it would appear, according to this approach,
that radiation-initiated events are not lost but can
remain dormant for at least 200 days when they can
be stimulated (promoted) by DES to develop into
mammary adenocarcinomas. Secondly, when the re-
sponse of the group that received both radiation
and DES 2 days before radiation is compared to the
response of the groups that received both radiation
and DES 50 days, or 100 days, or 200 days after ra-
diation, the response did not decline with increasing
interval between radiation and DES. The figures
were: -2 days DES = 62.7%; + 50 days = 52.3;
+ 100 days = 55.1; + 200 days = 77.8. The ratio of
-2 days to + 50 days, to + 100 days to + 200 days
was: 0.83; 0.88; 1.24. Again, clearly there was no reg-
ular decline in response as the interval between ra-
diation and DES treatments was increased. We
again conclude that radiation-initiated events can re-
main dormant for at last 200 days and susceptible to
DES stimulation or enhancement (promotion) for at
least 200 days. Yokoro et al. (11), studying mam-
mary carcinogenesis in W/F rats, has reached simi-
lar conclusions in regard to the prolactin enhance-
ment of chemical carcinogen-induced, X-ray-induced,
and neutron-induced events remaining dormant and
susceptible to promotion for a period of 7 months.
We conclude that radiation-initiated events can
remain susceptible, for long periods of time, to DES
hormonal promotion and that this finding is in gen-
eral accord with the initiation-promotion hypothesis
of carcinogenesis as put forward by Berenblum (12).
This may mean, if the rat radiation- induced mam-
mary adenocarcinoma system has meaning for the
radiation-induced human breast cancer situation-
and Shellabarger has given reasons (13) for why this
is so-that there may be previously initiated indi-
viduals who will develop breast cancer if they are
hormonally promoted. If true, this situation, in part,
suggests some of the difficulties inherent in assess-
ing the possible risks of compounds that are promo-
ters be they hormonal or nonhormonal promoters.
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